Cassava Sciences Updates Business Address

TL;DR

SAVA moved offices, no other news.

AI Summary

On July 1, 2024, Cassava Sciences, Inc. filed an 8-K report. The filing indicates a change in the company's business address to 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731. This filing does not appear to contain any material financial or operational updates beyond the address change.

Why It Matters

This filing primarily serves as a notification of a change in the company's physical location, which may be relevant for logistical or investor relations purposes.

Risk Assessment

Risk Level: low — The filing is a routine administrative update regarding a change of address and does not disclose any new material risks or events.

Key Players & Entities

• Cassava Sciences, Inc. (company) — Registrant
• 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731 (location) — New Business Address
• July 01, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value SAVA Nasdaq Capital Mark
• $2,000 — im, Dr. Wang was paid a cash stipend of $2,000 per month. He has also been awarded sto
• $4.22 — th a weighted average exercise price of $4.22 per share. Dr. Wang was previously a pa

Filing Documents

• form8-k.htm (8-K) — 66KB
• 0001493152-24-025725.txt ( ) — 285KB
• sava-20240701.xsd (EX-101.SCH) — 4KB
• sava-20240701_def.xml (EX-101.DEF) — 26KB
• sava-20240701_lab.xml (EX-101.LAB) — 36KB
• sava-20240701_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 01, 2024 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41905 91-1911336 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 6801 N Capital of Texas Highway , Building 1; Suite 300 Austin , Texas 78731 (Address of principal executive offices, including zip code) (512) 501-2444 (Registrant ' s telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below): Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value SAVA Nasdaq Capital Market Warrants, exercisable for shares of Common Stock* SAVAW Nasdaq Capital Market * In connection with the redemption of the Warrants on May 7, 2024, Nasdaq Stock Market LLC has filed a Form 25 relating to their removal from listing and deregistration under Section 12(b) of the Act. Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01. Other Events. Update on Government Investigations Cassava Sciences, Inc. ("Cassava" or the "Company") has been engaging with the U.S. Department of Justice (the "DOJ") and the U.S. Securities and Exchange Commission (the "SEC") in connection with ongoing investigations into the Company and two senior employees of the Company. Cassava is cooperating with the DOJ and SEC in connection with these investigations. In the course of ongoing discussions with the SEC regarding the Company's Phase 2b study of simufilam in Alzheimer's disease (the "Phase 2b Study"), the SEC recently provided the Company with new information obtained during its investigation. The Company's Board of Directors (the "Board") has empowered an Ad Hoc Investigation Committee (the "Committee"), comprising independent directors, to direct an investigation (the "Internal Investigation") of the information provided by the SEC. The Internal Investigation is also evaluating information contained in the DOJ indictment of Dr. Hoau-Yan Wang discussed below. This Committee, with the assistance of the Company's General Counsel, is supervising outside counsel conducting the Internal Investigation. The Committee is also empowered to oversee the Company's disclosures in filings with the SEC regarding matters at issue in the Internal Investigation. The Internal Investigation is continuing. Indictment of Dr. Hoau-Yan Wang On June 28, 2024, the DOJ announced that a federal grand jury in the U.S. District Court for the District of Maryland returned an indictment of Dr. Wang. The indictment alleges that Dr. Wang caused Cassava to submit grant applications to the U.S. National Institutes of Health ("NIH") that contained false and fraudulent representations about his research. Among other things, the indictment alleges that Dr. Wang made materially false, fraudulent, and misleading statements to NIH regarding the mechanism by which the Company's therapeutic product candidate, simufilam, was designed to treat Alzheimer's disease and the improvement of certain Alzheimer's disease indicators in patients treated with simufilam, and that Dr. Wang manipulated or otherwise fabricated research results, including Western Blot images that he prepared. Dr. Wang, who is employed as a professor at the School of Medicine of the City University of New York ("CUNY"), previously served as a scientific collaborator and advisor to Cassava. Dr. Wang's research, including foundational research published together with Dr. Lindsay Burns, Cassava's SVP, Neuroscience, led to the discovery of simufilam. Among other work

View Full Filing

View this 8-K filing on SEC EDGAR